Fate Therapeutics, Inc. (FATE)
2.435
+0.10
(+4.51%)
USD |
NASDAQ |
Aug 24, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Debt to Equity Ratio : 0.4932 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.4932 |
| March 31, 2026 | 0.4273 |
| December 31, 2025 | 0.3757 |
| September 30, 2025 | 0.3386 |
| June 30, 2025 | 0.3112 |
| March 31, 2025 | 0.2889 |
| December 31, 2024 | 0.2675 |
| September 30, 2024 | 0.2732 |
| June 30, 2024 | 0.2533 |
| March 31, 2024 | 0.2395 |
| December 31, 2023 | 0.281 |
| September 30, 2023 | 0.2606 |
| June 30, 2023 | 0.2429 |
| March 31, 2023 | 0.2254 |
| December 31, 2022 | 0.2259 |
| September 30, 2022 | 0.2141 |
| June 30, 2022 | 0.1935 |
| March 31, 2022 | 0.1792 |
| December 31, 2021 | 0.1691 |
| September 30, 2021 | 0.1493 |
| June 30, 2021 | 0.1469 |
| March 31, 2021 | 0.1404 |
| December 31, 2020 | 0.2531 |
| September 30, 2020 | 0.2014 |
| June 30, 2020 | 0.1709 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.3455 |
| December 31, 2019 | 0.11 |
| September 30, 2019 | 0.1538 |
| June 30, 2019 | 0.3339 |
| March 31, 2019 | 0.2922 |
| December 31, 2018 | 0.0928 |
| September 30, 2018 | 0.0855 |
| June 30, 2018 | 0.2865 |
| March 31, 2018 | 0.2281 |
| December 31, 2017 | 0.1918 |
| September 30, 2017 | 0.3233 |
| June 30, 2017 | 0.1209 |
| March 31, 2017 | 0.1363 |
| December 31, 2016 | 0.1461 |
| September 30, 2016 | 0.498 |
| June 30, 2016 | 0.6286 |
| March 31, 2016 | 0.5339 |
| December 31, 2015 | 0.4795 |
| September 30, 2015 | 0.4251 |
| June 30, 2015 | 0.3856 |
| March 31, 2015 | 0.9256 |
| December 31, 2014 | 0.6926 |
| September 30, 2014 | 0.2978 |
| June 30, 2014 | 0.0188 |
| March 31, 2014 | 0.0274 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
| Imunon, Inc. | 1.873 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 260.10M |
| Total Liabilities (Quarterly) | 106.66M |
| Shareholders Equity (Quarterly) | 153.44M |
| Current Ratio | 4.846 |
| Net Debt Paydown Yield | 0.49% |